Conference: 27 – 29 January 2021 Location: Berlin, Germany / also Live Stream & On- Demand Website: https://bit.ly/2FPoI56 With increased impact from the pandemic, pharma and biotech companies are under
Conference: 10 – 11 February 2021 Location: Online Virtual Event Website: https://www.smi-online.co.uk/pharmaceuticals/uk/conference/rna-therapeutics RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of
Conference: September 27th - 28th, 2021 (Porto, Portugal) Location: Alfandega Congress Center, R. Nova da Alfândega, 4050-430, Porto, Portugal Website: https://biotechpharmasummit.com The BioTech Pharma Summit will bring together the
Conference: 22 – 23 November 2021 Venue: London, UK Website: www.ophthalmicdrugs.com/farmavitawl Exploring the future of ocular drug development 4th Annual Ophthalmic Drugs Conference taking place on the 22nd and 23rd
Are you aware of new European Nitrosamine Regulations - EMA/511347/2019. There is serious workload expected from all marketing authorisation holders (MAH) in EU! Let’s see what is expected for MAH
What is a biological medicinal product? A biological medicinal product is a medicinal product that contains an active substance produced or excreted from biological sources (human, animal, or microbiological). Due
In August 2017, the Brazilian Health Surveillance Agency (ANVISA) published Resolution No. 168/2017, which establishes the administrative procedures related to ANVISA´s “prior consent” for the granting of pharmaceutical patent applications,
On average, big pharmaceutical companies spend around 20% of their budget in research and development of new drugs. For smaller companies, the effort can be even higher, up to 50%
Have you heard about this? The scam: Stealing more than $500,000 from buyers eager to acquire a miracle wearable. The product: BioRing, a device that was supposed to do everything
MHARA has publised GxP data integrity guidance for the industry. It addresses fundamental failures identified by MHRA and international regulatory partners during GLP, GCP, GMP and GDP inspections; many of
